Assignee
IMMUNITYBIO INC
US·45 granted patents·58 pending applications·37 citations·filing 2019–2025
Top patents by PatentIndex Score
103 records- 0195US12384852B2Genetically modified NK-92 cells having a safety switchIMMUNITYBIO INC·Filed 2021·Granted Aug 12, 2025·2 cites·20 claims
- 0295US12272439B1Distributed ledger for medicament administration trackingIMMUNITYBIO INC·Filed 2024·Granted Apr 8, 2025·2 cites·32 claims
- 0395US12109238B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2022·Granted Oct 8, 2024·2 cites·17 claims
- 0495US11547727B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Jan 10, 2023·10 cites·13 claims
- 0594US12492377B2Modified NK-92 haNK003 cells for the clinicIMMUNITYBIO INC·Filed 2023·Granted Dec 9, 2025·1 cites·19 claims
- 0694US11643452B2Fc-epsilon carIMMUNITYBIO INC·Filed 2021·Granted May 9, 2023·6 cites·8 claims
- 0793US12403178B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2023·Granted Sep 2, 2025·2 cites·22 claims
- 0892US2024366674A1Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 0990US12516112B2Single-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2024·Granted Jan 6, 2026·0 cites·20 claims
- 1090US12365874B2Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptorsIMMUNITYBIO INC·Filed 2021·Granted Jul 22, 2025·1 cites·18 claims
- 1190US2026078342A1MODIFIED NK-92 haNK003 CELLS FOR THE CLINICIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 1289US12473348B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 1389US12473347B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 1489US12016916B2Nant COVID vaccine cross reactivityIMMUNITYBIO INC·Filed 2023·Granted Jun 25, 2024·0 cites·20 claims
- 1588US12195520B2Advanced avatar dendritic cellsIMMUNITYBIO INC·Filed 2024·Granted Jan 14, 2025·0 cites·20 claims
- 1688US2025340664A1Genetically modified nk-92 cell lineIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 1787US12435122B2Fc-epsilon CARIMMUNITYBIO INC·Filed 2019·Granted Oct 7, 2025·3 cites·8 claims
- 1887US11813292B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2019·Granted Nov 14, 2023·2 cites·3 claims
- 1987US2025084150A1Advanced Avatar Dendritic CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 2086US12509494B2Multi-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2022·Granted Dec 30, 2025·0 cites·9 claims
- 2186US12398186B2Multi-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2022·Granted Aug 26, 2025·0 cites·29 claims
- 2286US12378300B2Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cellsIMMUNITYBIO INC·Filed 2020·Granted Aug 5, 2025·1 cites·19 claims
- 2386US12168052B2Nant COVID vaccine cross reactivityIMMUNITYBIO INC·Filed 2024·Granted Dec 17, 2024·0 cites·16 claims
- 2484US11911459B2Nant COVID vaccine cross reactivityIMMUNITYBIO INC·Filed 2022·Granted Feb 27, 2024·0 cites·18 claims
- 2584US2024424088A1Nant COVID Vaccine Cross ReactivityIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 2683US12180283B2Anti-B7-H4 chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Dec 31, 2024·1 cites·21 claims
- 2783US12064450B2Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2022·Granted Aug 20, 2024·0 cites·11 claims
- 2882US11975027B2Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2021·Granted May 7, 2024·0 cites·8 claims
- 2981US12290558B2SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogensIMMUNITYBIO INC·Filed 2023·Granted May 6, 2025·0 cites·11 claims
- 3081US2024319198A1Biological Deposit Labeling And TrackingIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3180US12274748B2Adenoviral vector transduced apheresis productIMMUNITYBIO INC·Filed 2024·Granted Apr 15, 2025·0 cites·6 claims
- 3280US11453862B2Mononuclear cell derived NK cellsIMMUNITYBIO INC·Filed 2019·Granted Sep 27, 2022·2 cites·16 claims
- 3380US2025073305A1Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)IMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3480US2025019716A1Methods And Systems For Producing A Protein Of Interest In A PlantIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3579US12043656B2Advanced avatar dendritic cellsIMMUNITYBIO INC·Filed 2022·Granted Jul 23, 2024·0 cites·17 claims
- 3678US2025170181A1Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 3778US2024002802A1Modified nk-92 cells for treating cancerIMMUNITYBIO INC·Filed 2023·Application pending·0 cites
- 3877US2025066484A1Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 3977US2025115870A1Mononuclear Cell Derived NK CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4077US2025066500A1Methods of treating age-related and inflammatory diseasesIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4176US2024366972A1Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4276US2024252540A1Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironmentIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4375US12479899B2Multi-chain chimeric polypeptides and uses thereofIMMUNITYBIO INC·Filed 2023·Granted Nov 25, 2025·0 cites·38 claims
- 4475US2025270282A1Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cellsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 4574US12584138B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesIMMUNITYBIO INC·Filed 2021·Granted Mar 24, 2026·0 cites·13 claims
- 4674US2023272042A1Fc-epsilon carIMMUNITYBIO INC·Filed 2023·Application pending·0 cites
- 4773US12180492B2Methods and systems for producing a protein of interest in a plantIMMUNITYBIO INC·Filed 2022·Granted Dec 31, 2024·0 cites·20 claims
- 4873US2025109409A1RIG1 Inhibition and Therapeutic Viral Protein ExpressionIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4973US2025011718A1Ex Vivo Generation of Immune Effector Cells from Apheresis Material IntermediatesIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 5073US2025011380A1Methods of treating aging-related disordersIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 103 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →